Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer

NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral artesunate can reverse pre-cancerous changes in the cervix and prevent the development and progression of invasive cancer. Findings from this study will increase our understanding of the effects of artesunate on CIN2/3 and if confirmatory inform future clinical studies.

NCT Number	NCT07095478
Lead Sponsor	Metanoic Health Ltd. Collaborators: Clinical Research Malaysia
Conditions	CIN 2/3
Enrollment	28 participants
Start Date	2025-08-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-07-31